Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Immunol. 2012 Oct;24(5):640-8. doi: 10.1016/j.coi.2012.08.002. Epub 2012 Aug 29.

The road to purified hematopoietic stem cell transplants is paved with antibodies.

Author information

1
Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, United States.

Abstract

Hematopoietic progenitor cell replacement therapy remains a surprisingly unrefined process. In general, unmanipulated bone marrow or mobilized peripheral blood (MPB) grafts which carry potentially harmful passenger cells are administered after treating recipients with high-dose chemotherapy and/or radiotherapy to eradicate malignant disease, eliminate immunologic barriers to allogeneic cell engraftment, and to 'make space' for rare donor stem cells within the stem cell niche. The sequalae of such treatments are substantial, including direct organ toxicity and nonspecific inflammation that contribute to the development of graft-versus-host disease (GVHD) and poor immune reconstitution. Passenger tumor cells that contaminate autologous hematopoietic grafts may contribute to relapse post-transplant. Use of antibodies to rid grafts of unwanted cell populations, and to eliminate or minimize the need for nonspecifically cytotoxic therapies used to condition transplant recipients, will dramatically improve the safety profile of allogeneic and gene-modified autologous hematopoietic stem cell therapies.

PMID:
22939368
PMCID:
PMC5061494
DOI:
10.1016/j.coi.2012.08.002
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

ILW co-founded SyStemix, Inc., which performed the CD34+CD90+ HSC selection in the trials discussed in this review, but currently has no financial interest in the technology as SyStemix, Inc., is now a wholly owned subsidiary of Novartis, Inc. ACL and JAS have no relevant conflicts of interest to disclose.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center